imugene.com Report : Visit Site


  • Ranking Alexa Global: # 16,088,519

    Server:Apache...

    The main IP address: 134.0.20.66,Your server United Kingdom,Farnborough ISP:Wirehive Limited  TLD:com CountryCode:GB

    The description :home about us board of directors and management scientific advisory board corporate governance products her-vaxx clinical trials intellectual property publications arginine modulators mimotopes busine...

    This report updates in 13-Jun-2018

Created Date:2002-07-30
Changed Date:2017-07-10

Technical data of the imugene.com


Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host imugene.com. Currently, hosted in United Kingdom and its service provider is Wirehive Limited .

Latitude: 51.294239044189
Longitude: -0.7556499838829
Country: United Kingdom (GB)
City: Farnborough
Region: England
ISP: Wirehive Limited

the related websites

HTTP Header Analysis


HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

Transfer-Encoding:chunked
Set-Cookie:PHPSESSID=50aa1ad7f76998e6d12c396330f83463; path=/, www_pyrocms=YcFz%2B5bmtUdIss0022xLA1366aqAD4MqiP4Mg7GbWpfdgFoUYj%2FzsrtpgYT%2FSB9cJCLPJ6Dx2oz7t0TLLZiLTbCP3DtaRncO4NBiy7UxvW%2B3lHdozEbLOsiL9N5VlWjXmunRSo9CISRWbGckvNLr9jt74eXlSc79xCKEsWRai%2BsNHZhJxA1vIQF05OE5ntW5iAGpAnvYFnAQZVYvUXse%2F3ZuVXnZB%2Fn3S8UlR1xg1RzoQaHaZofj5YIRXPRn8ohQnbEEPaBNdx9wpk5F75jE82wQBQzBftVW6EoAplxkkufr4EMPRSVQSe7Pwnu6HLQJG45u726hp8Svr%2B0RFLMZ4RZaf5lp%2BJWNced3m1urlJWkReZE898XPaBEqnwljuwZ; path=/; domain=www.imugene.com
Expires:Thu, 19 Nov 1981 08:52:00 GMT
Server:Apache
Connection:close
Pragma:no-cache
Cache-Control:no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Date:Wed, 13 Jun 2018 00:00:53 GMT
Content-Type:text/html; charset=UTF-8

DNS

soa:ns1.melbourneit.net. admin.melbourneit.net. 2018031901 86400 7200 3600000 172800
txt:"v=spf1 include:spf.protection.outlook.com -all"
"MS=ms33373965"
ns:ns3.melbourneit.net.
ns2.melbourneit.net.
ns1.melbourneit.net.
ns4.melbourneit.net.
ipv4:IP:134.0.20.66
ASN:56730
OWNER:WIREHIVE-AS, GB
Country:GB
mx:MX preference = 0, mail exchanger = imugene-com.mail.protection.outlook.com.

HtmlToText

home about us board of directors and management scientific advisory board corporate governance products her-vaxx clinical trials intellectual property publications arginine modulators mimotopes business development investor center analyst coverage annual reports asx announcements investor presentations media coverage newsletters immuno-oncology industry news imugene videos contact home about us board of directors and management scientific advisory board corporate governance products her-vaxx clinical trials intellectual property publications arginine modulators mimotopes business development investor center analyst coverage annual reports asx announcements investor presentations media coverage newsletters immuno-oncology industry news imugene videos contact imugene ltd is building a pipeline of b-cell peptide cancer vaccines imugene (asx; imu) is an immuno-oncology focused biopharmaceutical company developing her-2+ gastric and breast cancer immunotherapies. our mission is to build a pipeline of b-cell peptide cancer vaccines. view md/ceo leslie chong being interviewed by commsec's tom piotrowski 6 april 2018 ( click here ). view 2017 imugene immuno-oncology expert briefing featuring dr axel hoos, prof dr christoph zielinski and prof dr ursula wiedermann ( click here ) our lead product is her-vaxx , a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to her-2/neu, the same biomarker targeted by the $us6.9 billion per annum drug herceptin®. click here to view latest imugene fact sheet click here to view video that introduces her-vaxx and explains how it works click here to view imugene's current share price click here to view leslie chong interview with medicalresearch.com "imugene building pipeline of b cell peptide cancer vaccines". click here to read "what's hot & what's not in immuno-oncology licensing. dr axel hoos is interviewed as part of an expert panel. her-vaxx has successfully completed a phase 1 study in breast cancer and has commenced in 2017 a phase 1b/2 study in her2+ gastric cancer. gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year. her-vaxx has shown success in stimulating the production of lifesaving her-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. its further development is directed towards providing a natural, potentially more potent alternative to roche’s popular injectable antibody, herceptin®, which have become one of the world’s bestselling cancer drugs with annual sales in excess of $us6.7 billion (roche investor update 30/1/17). imugene in partnership with the medical university of vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. this partnership has the potential to create game-changing b cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies. imugene is also building a pipeline of small molecule immuno-oncology drugs. arginine is a critical amino acid for the health of cancer fighting t-cells and depletion of it limits the effectiveness of t-cells to fight tumours. we are leveraging our core expertise in tumor biology and medicinal chemistry to develop small molecule selective arginine modulators. imugene’s corporate headquarters are located in melbourne, australia with most of the scientific team in vienna, austria. latest news 07/06/2018 capital raising presentation 07/06/2018 prospectus 07/06/2018 imugene to raise a$20.1 million home about us board of directors scientific advisory board products her-vaxx clinical trials intellectual property publications mimotopes business development investor center analyst coverage annual reports asx announcements investor presentations media coverage newsletters immuno-oncology industry news contact us twitter facebook linkedin share trading policies privacy policy forward looking statement © imugene 2018. all rights reserved. abn 99 009 179 551

URL analysis for imugene.com


http://www.imugene.com/share-trading-policies
http://www.imugene.com/files/download/242
http://www.imugene.com/products/clinical-trials
http://www.imugene.com/privacy-policy
http://www.imugene.com/company/board-of-directors-and-management
http://www.imugene.com/files/download/174
http://www.imugene.com/uploads/default/files/3._capital_raising_presentation_(final).pdf
http://www.imugene.com/products/publications
http://www.imugene.com/products/intellectual-property
http://www.imugene.com/investor-center/imugene-videos
http://www.imugene.com/uploads/default/files/capital_raise_announcement[1].pdf
http://www.imugene.com/investor-center/annual-reports
http://www.imugene.com/contact
http://www.imugene.com/products/her-vaxx
http://www.imugene.com/investor-center/media-coverage

Whois Information


Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: IMUGENE.COM
Registry Domain ID: 88860821_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.netregistry.net
Registrar URL: http://www.netregistry.com.au
Updated Date: 2017-07-10T09:55:04Z
Creation Date: 2002-07-30T08:41:49Z
Registry Expiry Date: 2019-07-30T08:41:49Z
Registrar: NetRegistry Pty. Ltd.
Registrar IANA ID: 677
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: ok https://icann.org/epp#ok
Name Server: NS1.YOURDNSHOST.NET
Name Server: NS2.YOURDNSHOST.NET
Name Server: NS3.YOURDNSHOST.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-10-08T22:20:03Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR NetRegistry Pty. Ltd.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =imugene.com

  PORT 43

  TYPE domain

DOMAIN

  NAME imugene.com

  CHANGED 2017-07-10

  CREATED 2002-07-30

STATUS
ok https://icann.org/epp#ok

NSERVER

  NS1.YOURDNSHOST.NET 203.55.143.10

  NS2.YOURDNSHOST.NET 203.55.142.11

  NS3.YOURDNSHOST.NET 203.55.143.100

  REGISTERED yes

Go to top

Mistakes


The following list shows you to spelling mistakes possible of the internet users for the website searched .

  • www.uimugene.com
  • www.7imugene.com
  • www.himugene.com
  • www.kimugene.com
  • www.jimugene.com
  • www.iimugene.com
  • www.8imugene.com
  • www.yimugene.com
  • www.imugeneebc.com
  • www.imugeneebc.com
  • www.imugene3bc.com
  • www.imugenewbc.com
  • www.imugenesbc.com
  • www.imugene#bc.com
  • www.imugenedbc.com
  • www.imugenefbc.com
  • www.imugene&bc.com
  • www.imugenerbc.com
  • www.urlw4ebc.com
  • www.imugene4bc.com
  • www.imugenec.com
  • www.imugenebc.com
  • www.imugenevc.com
  • www.imugenevbc.com
  • www.imugenevc.com
  • www.imugene c.com
  • www.imugene bc.com
  • www.imugene c.com
  • www.imugenegc.com
  • www.imugenegbc.com
  • www.imugenegc.com
  • www.imugenejc.com
  • www.imugenejbc.com
  • www.imugenejc.com
  • www.imugenenc.com
  • www.imugenenbc.com
  • www.imugenenc.com
  • www.imugenehc.com
  • www.imugenehbc.com
  • www.imugenehc.com
  • www.imugene.com
  • www.imugenec.com
  • www.imugenex.com
  • www.imugenexc.com
  • www.imugenex.com
  • www.imugenef.com
  • www.imugenefc.com
  • www.imugenef.com
  • www.imugenev.com
  • www.imugenevc.com
  • www.imugenev.com
  • www.imugened.com
  • www.imugenedc.com
  • www.imugened.com
  • www.imugenecb.com
  • www.imugenecom
  • www.imugene..com
  • www.imugene/com
  • www.imugene/.com
  • www.imugene./com
  • www.imugenencom
  • www.imugenen.com
  • www.imugene.ncom
  • www.imugene;com
  • www.imugene;.com
  • www.imugene.;com
  • www.imugenelcom
  • www.imugenel.com
  • www.imugene.lcom
  • www.imugene com
  • www.imugene .com
  • www.imugene. com
  • www.imugene,com
  • www.imugene,.com
  • www.imugene.,com
  • www.imugenemcom
  • www.imugenem.com
  • www.imugene.mcom
  • www.imugene.ccom
  • www.imugene.om
  • www.imugene.ccom
  • www.imugene.xom
  • www.imugene.xcom
  • www.imugene.cxom
  • www.imugene.fom
  • www.imugene.fcom
  • www.imugene.cfom
  • www.imugene.vom
  • www.imugene.vcom
  • www.imugene.cvom
  • www.imugene.dom
  • www.imugene.dcom
  • www.imugene.cdom
  • www.imugenec.om
  • www.imugene.cm
  • www.imugene.coom
  • www.imugene.cpm
  • www.imugene.cpom
  • www.imugene.copm
  • www.imugene.cim
  • www.imugene.ciom
  • www.imugene.coim
  • www.imugene.ckm
  • www.imugene.ckom
  • www.imugene.cokm
  • www.imugene.clm
  • www.imugene.clom
  • www.imugene.colm
  • www.imugene.c0m
  • www.imugene.c0om
  • www.imugene.co0m
  • www.imugene.c:m
  • www.imugene.c:om
  • www.imugene.co:m
  • www.imugene.c9m
  • www.imugene.c9om
  • www.imugene.co9m
  • www.imugene.ocm
  • www.imugene.co
  • imugene.comm
  • www.imugene.con
  • www.imugene.conm
  • imugene.comn
  • www.imugene.col
  • www.imugene.colm
  • imugene.coml
  • www.imugene.co
  • www.imugene.co m
  • imugene.com
  • www.imugene.cok
  • www.imugene.cokm
  • imugene.comk
  • www.imugene.co,
  • www.imugene.co,m
  • imugene.com,
  • www.imugene.coj
  • www.imugene.cojm
  • imugene.comj
  • www.imugene.cmo
Show All Mistakes Hide All Mistakes